Clinical Trial Update: Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase [Phase 2]

View source ↗

Summary

A Phase 2 trial tested a peptide vaccine made from MART-1, GP100, and Tyrosinase in HLA-A201 patients with metastatic melanoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MART-1/GP100/Tyrosinase peptide vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Neoplasm Metastasis | Phase 2 | Status: COMPLETED